FDA Drug Safety Committee Questions Expanded AER System

Rx-to-OTC switch drugs should be an area of focus as FDA determines possible gaps in its postmarket drug surveillance system, according to FDA Drug Safety & Risk Management Advisory Committee member Ruth Day, PhD, Duke University